iPSC– tag –
-
Twenty Years of iPSCs: From Bespoke Models to Standardized Engineered Biologics
Nature Medicine International Overview Marking two decades since their discovery, a seminal review by Joseph Wu and colleagues in *Cell Stem Cell* chronicles the remarkable evolution of induced pluripotent stem cell (iPSC) technology. Th... -
Comprehensive Analysis Reveals iPSC Potential in CAR-T Therapy for Cancer, Highlights Key Challenges
Research Journal of Pharmacy and Technology India Overview A comprehensive review analyzes the therapeutic potential and inherent risks of hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells... -
Overcoming Commercialization Hurdles for iPSC Therapeutics: Regulatory Compliance and Accessible Manufacturing Strategies
Technology Networks Unknown Overview Commercializing iPSC-based therapeutics faces significant challenges in regulatory compliance and ensuring patient accessibility, as many therapies originate from academic settings without large-scale... -
Fate Therapeutics to Announce iPSC-Derived Immunocellular Therapy Strategy at 2026 Cantor Conference
GlobeNewswire USA Overview Fate Therapeutics announced its participation in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference. The company holds a leading position in creating multi-gene-edited iPSC lines and manufac... -
Panasonic and Kyoto University CiRA Foundation Develop Fully Automated iPSC Establishment System to Accelerate Regenerative Medicine Adoption
Panasonic Holdings (Facebook post) Japan Overview Panasonic Holdings and the Kyoto University iPS Cell Research Institute (CiRA) Foundation have collaboratively developed a groundbreaking automated system for establishing iPS cells from ... -
REPROCELL Accelerates Clinical Production with FDA/EMA/PMDA-Compliant iPSC Manufacturing Platform
REPROCELL Japan Overview REPROCELL has unveiled a robust iPSC manufacturing scale-up strategy aimed at accelerating clinical development and commercialization of iPSC-based therapeutics. Their StemRNA™ Clinical iPSC Platform offers clini... -
REPROCELL Publishes Article on Scaling iPSC Manufacturing: Addressing Challenges from Cell Line Development to Clinical Production
REPROCELL Japan Overview REPROCELL has published an article titled "Scaling iPSC Manufacturing: From Cell Line Development to Clinical Production," focusing on the crucial aspects of industrializing induced pluripotent stem cell (iPSC) t... -
Fate Therapeutics to Present on iPSC-Derived CAR T Cell Candidate FT819 for Autoimmune Diseases at 2026 Cantor Global Healthcare Conference
Stock Titan USA Overview Fate Therapeutics announced its participation in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 9th, where it will discuss its off-the-shelf iPSC-derived CAR T cell candidate FT819 f... -
Fate Therapeutics Initiates Phase 1/2 Trial for Novel Cell Therapy FT839 in Autoimmune Diseases, Expanding Pipeline
TipRanks.com USA Overview Fate Therapeutics has launched a Phase 1/2 dose-escalation and expansion trial for its novel cell therapy candidate, FT839, in patients with autoimmune diseases. This intravenously administered therapy is design... -
Fate Therapeutics Initiates Phase 2 RECLAIM-LN Trial for Lupus Nephritis with Off-the-Shelf iPSC-Derived CD19 CAR-T Cell Therapy FT819
Seeking Alpha USA Overview Fate Therapeutics has commenced its Phase 2 RECLAIM-LN trial for lupus nephritis, administering the first patient with its iPSC-derived CD19 CAR-T cell therapy, FT819, in an outpatient setting. This marks a sig...
